Adding Talent & Technologies
Sartorius has leading market positions in core technologies and is continuously expanding its portfolio by new, complementary technologies that help our biopharma customers develop and manufacture medications faster and more easily. Integrating innovations through acquisitions is one of the pillars of our innovative power and part of our growth strategy.
In recent years, Sartorius has been continuously making acquisitions, including:
- Solutions for production of cell & gene therapies and vaccines
- Systems for cell and protein analysis
- Chromatography and tangential flow filtration systems
- Cell culture media
- Bioprocessing software
Explore Our Recent Acquisitions
We are excited to join forces with a world class bioprocess market leader as Sartorius. Our combined portfolios will create a unique ability to optimize the total process workflow to deliver unparalleled value for cell/gene and DNA/RNA therapy customers, in a strong effort to make these critical needed therapies more affordable.